NewEdge Wealth’s Anixa Biosciences ANIX Stock Holding History

NewEdge Wealth’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35K	Hold	12,500	–	–	﹤0.01%	1223
2026 Q1	$32.3K	Hold	12,500	–	–	﹤0.01%	1118
2025 Q4	$39K	Hold	12,500	–	–	﹤0.01%	1184
2025 Q3	$50.9K	Hold	12,500	–	–	﹤0.01%	1013
2025 Q2	$37.6K	Buy	+12,500	New	+$35.7K	﹤0.01%	958

Other funds holding ANIX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

NewEdge Wealth's ANIX Position: Q2 2026 in Review

NewEdge Wealth held its Anixa Biosciences (ANIX) position steady in Q2 2026 at 12,500 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #1223.

NewEdge Wealth first reported a position in ANIX in Q2 2025 and has held it in 5 quarters since. The position peaked at $50.9K in Q3 2025. 63 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

NewEdge Wealth held 12,500 shares of Anixa Biosciences worth $35K as of Q2 2026.
NewEdge Wealth left its Anixa Biosciences share count unchanged in Q2 2026.
Anixa Biosciences made up ﹤0.01% of NewEdge Wealth's portfolio in Q2 2026, its #1223 holding.
NewEdge Wealth first reported a position in Anixa Biosciences in Q2 2025 and has held it in 5 quarters since.
NewEdge Wealth's Anixa Biosciences position peaked at $50.9K in Q3 2025.
63 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on NewEdge Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.